Oligonucleotide-based therapies, such as small-interfering RNA and antisense oligonucleotide, have been developed in recent years for the treatment of MASLD by reducing the expression of the PNPLA3 gene carrying the genetic variant. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.